LOS ANGELES, CA - February 13, 2026 (NEWMEDIAWIRE) - HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through its HeartBeam System, a cable-free, high-fidelity ECG platform designed to capture the heart’s electrical signals from three distinct directions and synthesize them into a 12-lead ECG for arrhythmia assessment.

• HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.
• HeartBeam’s technology is aligned with evolving regulatory and clinical priorities.
• In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report.

The company was included in a report published by Modern Healthcare and authored by Lauren Dubinsky. The report examined recent FDA activity across the medical device landscape, highlighting companies that achieved meaningful regulatory milestones or demonstrated forward momentum…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View the original release on www.newmediawire.com

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is HeartBeam (BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year.